An alleged faster and vastly more effective treatment for drug-resistant tuberculosis is being rolled out in the Asia-Pacific region, raising hopes of a "new era" in tackling one of the world's deadliest infectious diseases.

The treatment, known as BPaL, combines the antibiotics bedaquiline, pretomanid and linezolid, and has received regulatory approval in more than 60 countries since 2019, according to the non-profit TB Alliance, which developed it.

According to figures shown by the World Health Organization, Asia had most of the world's new TB cases in 2022, and recorded over five hundred thousand deaths under the year in review.

TB has been reported to be treated with antibiotics, more than three percent of new TB patients are resistant to commonly prescribed drugs.

Until recently, treatment for these patients involved daily painful injections or a fistful of pills for 18 months or longer, while some endured severe side effects such as nausea and, in extreme cases, blindness.

Many people prematurely quit their treatment, which had a success rate of 63 percent or lower.

Now, a new drug regimen involving fewer pills and side effects is being rolled out in the Asia-Pacific, including the Philippines, Vietnam and Indonesia, where trials have shown a more than 90 percent cure rate after six months.